Omega Therapeutics Analyst Ratings
Omega Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 640.74% | HC Wainwright & Co. | $11 → $12 | Maintains | Buy |
| 11/10/2023 | 640.74% | Wedbush | $19 → $12 | Maintains | Outperform |
| 09/01/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 08/04/2023 | 640.74% | Chardan Capital | → $12 | Reiterates | Buy → Buy |
| 06/06/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | Buy → Buy |
| 05/08/2023 | 640.74% | Chardan Capital | → $12 | Reiterates | → Buy |
| 03/31/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 03/24/2023 | 579.01% | HC Wainwright & Co. | → $11 | Reiterates | → Buy |
| 03/10/2023 | 579.01% | JonesTrading | → $11 | Initiates Coverage On | → Buy |
| 03/03/2023 | 517.28% | Piper Sandler | $8 → $10 | Maintains | Overweight |
| 12/08/2022 | 579.01% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 09/23/2022 | 640.74% | Chardan Capital | → $12 | Initiates Coverage On | → Buy |
| 05/24/2022 | 146.91% | Goldman Sachs | $7 → $4 | Maintains | Neutral |
| 05/23/2022 | 332.1% | Piper Sandler | $30 → $7 | Maintains | Overweight |
| 08/24/2021 | 2122.22% | Wedbush | → $36 | Initiates Coverage On | → Outperform |
| 08/24/2021 | 1751.85% | Jefferies | → $30 | Initiates Coverage On | → Buy |
| 08/24/2021 | 1751.85% | Piper Sandler | → $30 | Initiates Coverage On | → Overweight |
| 08/24/2021 | 1258.02% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/13/2023 | 640.74% | HC Wainwright & Co. | 11 美元 → 12 美元 | 维护 | 买 |
| 11/10/2023 | 640.74% | Wedbush | 19 美元 → 12 美元 | 维护 | 跑赢大盘 |
| 09/01/2023 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | 购买 → 购买 |
| 08/04/2023 | 640.74% | 查丹资本 | → 12 美元 | 重申 | 购买 → 购买 |
| 06/06/2023 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | 购买 → 购买 |
| 05/08/2023 | 640.74% | 查丹资本 | → 12 美元 | 重申 | → 购买 |
| 03/31/2023 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | → 购买 |
| 2023 年 3 月 24 日 | 579.01% | HC Wainwright & Co. | → 11 美元 | 重申 | → 购买 |
| 03/10/2023 | 579.01% | JonesTrading | → 11 美元 | 启动覆盖范围开启 | → 购买 |
| 03/03/2023 | 517.28% | 派珀·桑德勒 | 8 美元 → 10 美元 | 维护 | 超重 |
| 2022 年 8 月 12 日 | 579.01% | HC Wainwright & Co. | → 11 美元 | 启动覆盖范围开启 | → 购买 |
| 09/23/2022 | 640.74% | 查丹资本 | → 12 美元 | 启动覆盖范围开启 | → 购买 |
| 2022 年 5 月 24 日 | 146.91% | 高盛 | 7 美元 → 4 美元 | 维护 | 中立 |
| 05/23/2022 | 332.1% | 派珀·桑德勒 | 30 美元 → 7 美元 | 维护 | 超重 |
| 08/24/2021 | 2122.22% | Wedbush | → 36 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 08/24/2021 | 1751.85% | 杰富瑞集团 | → 30 美元 | 启动覆盖范围开启 | → 购买 |
| 08/24/2021 | 1751.85% | 派珀·桑德勒 | → 30 美元 | 启动覆盖范围开启 | → 超重 |
| 08/24/2021 | 1258.02% | 高盛 | → 22 美元 | 启动覆盖范围开启 | → 中立 |
What is the target price for Omega Therapeutics (OMGA)?
Omega Therapeutics（OMGA）的目标价格是多少？
The latest price target for Omega Therapeutics (NASDAQ: OMGA) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $12.00 expecting OMGA to rise to within 12 months (a possible 640.74% upside). 11 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月13日公布了欧米茄疗法（纳斯达克股票代码：OMGA）的最新目标股价。该分析公司将目标股价定为12.00美元，预计OMGA将在12个月内升至12个月内（可能上涨640.74％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Omega Therapeutics (OMGA)?
分析师对 Omega Therapeutics（OMGA）的最新评级是多少？
The latest analyst rating for Omega Therapeutics (NASDAQ: OMGA) was provided by HC Wainwright & Co., and Omega Therapeutics maintained their buy rating.
HC Wainwright & Co. 对欧米茄疗法（纳斯达克股票代码：OMGA）的最新分析师评级由HC Wainwright & Co. 提供，欧米茄疗法维持买入评级。
When is the next analyst rating going to be posted or updated for Omega Therapeutics (OMGA)?
Omega Therapeutics（OMGA）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Omega Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Omega Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与欧米茄疗法的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。欧米茄疗法的最新评级是在2023年11月13日发布的，因此您应该预计下一个评级将在2024年11月13日左右公布。
Is the Analyst Rating Omega Therapeutics (OMGA) correct?
分析师对欧米茄疗法（OMGA）的评级正确吗？
While ratings are subjective and will change, the latest Omega Therapeutics (OMGA) rating was a maintained with a price target of $11.00 to $12.00. The current price Omega Therapeutics (OMGA) is trading at is $1.62, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的欧米茄疗法（OMGA）评级维持不变，目标股价为11.00美元至12.00美元。欧米茄疗法（OMGA）目前的交易价格为1.62美元，超出了分析师的预期区间。